期刊文献+

Analysis of risk factors for central venous port failure in cancer patients 被引量:12

Analysis of risk factors for central venous port failure in cancer patients
下载PDF
导出
摘要 AIM: To analyze the risk factors for central port failure in cancer patients administered chemotherapy, using univariate and multivariate analyses. METHODS: A total of 1348 totally implantable venous access devices (TIVADs) were implanted into 1280 cancer patients in this cohort study. A Cox proportional hazard model was applied to analyze risk factors for failure of TIVADs. Log-rank test was used to compare actuarial survival rates. Infection, thrombosis, and surgical complication rates (χ2 test or Fisher's exact test) were compared in relation to the risk factors. RESULTS: Increasing age, male gender and openended catheter use were signifi cant risk factors reducing survival of TIVADs as determined by univariate and multivariate analyses. Hematogenous malignancy decreased the survival time of TIVADs; this reduction was not statistically signifi cant by univariate analysis [hazard ratio (HR) = 1.336, 95% CI: 0.966-1.849, P = 0.080)]. However, it became a signifi cant risk factor by multivariate analysis (HR = 1.499, 95% CI: 1.079-2.083, P = 0.016) when correlated with variables of age, sex and catheter type. Close-ended (Groshong) catheters had a lower thrombosis rate than open-ended catheters (2.5% vs 5%, P = 0.015). Hematogenous malignancy had higher infection rates than solid malignancy (10.5% vs 2.5%, P < 0.001). CONCLUSION: Increasing age, male gender, openended catheters and hematogenous malignancy were risk factors for TIVAD failure. Close-ended catheters had lower thrombosis rates and hematogenous malignancy had higher infection rates. AIM: To analyze the risk factors for central port failure in cancer patients administered chemotherapy, using univariate and multivariate analyses. METHODS: A total of 1348 totally implantable venous access devices (TIVADs) were implanted into 1280 cancer patients in this cohort study. A Cox proportional hazard model was applied to analyze risk factors for failure of TIVADs. Log-rank test was used to compare actuarial survival rates. Infection, thrombosis, and surgical complication rates (Χ^2 test or Fisher's exact test) were compared in relation to the risk factors. RESULTS: Increasing age, male gender and open- ended catheter use were significant risk factors reducing survival of TIVADs as determined by univariate and multivariate analyses. Hematogenous malignancy decreased the survival time of TIVADs; this reduction was not statistically significant by univariate analysis [hazard ratio (HR) = 1.336, 95% CI: 0.966-1.849, P = 0.080)]. However, it became a significant risk factor by multivariate analysis (HR = 1.499, 95% CI: 1.079-2.083, P = 0.016) when correlated with variables of age, sex and catheter type. Close-ended (Groshong) catheters had a lower thrombosis rate than open-ended catheters (2.5% vs 5%, P = 0.015). Hematogenous malignancy had higher infection rates than solid malignancy (10.5% vs 2.5%, P 〈 0.001).CONCLUSION: Increasing age, male gender, open- ended catheters and hematogenous malignancy were risk factors for TIVAD failure. Close-ended catheters had lower thrombosis rates and hematogenous malig- nancy had higher infection rates.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第37期4709-4714,共6页 世界胃肠病学杂志(英文版)
关键词 风险因素 端口 静脉 患者 癌症 中央 Central venous port Chemotherapy Risk factor Cancer patient Multivariate analysis
  • 相关文献

参考文献20

  • 1Broviac JW, Cole JJ, Scribner BH. A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet 1973; 136:602-606.
  • 2Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 1979; 148:871-875.
  • 3Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 1982; 92:706-712.
  • 4Biffi R, Corrado F, de Braud F, de Lucia F, Scarpa D, Testori A, Orsi F, Bellomi M, Mauri S, Aapro M, Andreoni B. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer 1997; 33:1190-1194.
  • 5Biffi R, De Braud F, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N, Robertson C, Bellomi M, Andreoni B. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001; 92:1204-1212.
  • 6Stanislav GV, Fitzgibbons RJ Jr, Bailey RT Jr, Mailliard JA, Johnson PS, Feole JB. Reliability of implantable central venous access devices in patients with cancer. Arch Surg 1987; 122:1280-1283.
  • 7Gyves JW, Ensminger WD, Niederhuber JE, Dent T, Walker S, Gilbertson S, Cozzi E, Saran P. A totally implanted injection port system for blood sampling and chemotherapy administration. JAMA 1984; 251:2538-2541.
  • 8Bothe A Jr, Piccione W, Ambrosino JJ, Benotti PN, Lokich JJ. Implantable central venous access system. Am J Surg 1984; 147:565-569.
  • 9Harvey WH, Pick TE, Reed K, Solenberger RI. A prospective evaluation of the Port-A-Cath implantable venous access system in chronically ill adults and children. Surg Gynecol Obstet 1989; 169:495-500.
  • 10Hou SM, Wang PC, Sung YC, Lee HH, Liu HT, Chen YH. Comparisons of outcomes and survivals for two central venous access port systems. J Surg Oncol 2005; 91:61-66.

同被引文献79

引证文献12

二级引证文献209

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部